Bupivacaine buccal - Moberg Pharma

Drug Profile

Bupivacaine buccal - Moberg Pharma

Alternative Names: BUPI; BUPI-25; Bupizenge

Latest Information Update: 20 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Oracain
  • Developer Hvidovre Hospital; Moberg Pharma
  • Class Anilides; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Dental pain; Inflammatory pain

Most Recent Events

  • 19 Oct 2016 Moberg Pharma has patent protection for bupivacaine buccal in European Union
  • 16 Aug 2016 Hvidovre University Hospital and Moberg Pharma discontinue a phase II trial for Inflammatory pain in Denmark (EudarCT2013-000343-11)
  • 28 Mar 2016 Moberg Pharma plans two phase-III trials for Pain in Europe and India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top